[8-K] Viridian Therapeutics, Inc.\DE Reports Material Event
Viridian Therapeutics (VRDN) announced a preliminary balance of approximately $490.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025. The figure is unaudited and subject to completion of financial closing procedures, and the company’s independent auditor has not performed any review or assurance work on this number. The final amount reported in the upcoming unaudited condensed consolidated balance sheet may differ materially.
Viridian Therapeutics (VRDN) ha annunciato un saldo preliminare di circa $490.9 milioni in contanti, equivalenti in contanti e titoli negoziabili al 30 settembre 2025. La cifra è non revisionata e soggetta al completamento delle procedure di chiusura finanziaria, e l'auditor indipendente della società non ha eseguito alcuna revisione o attività di assicurazione su tale importo. L'importo finale riportato nel prossimo bilancio consolidato condensato non revisionato potrebbe differire in modo sostanziale.
Viridian Therapeutics (VRDN) anunció un saldo preliminar de aproximadamente $490.9 millones en efectivo, equivalentes de efectivo y valores negociables al 30 de septiembre de 2025. La cifra es no audita y sujeta a la finalización de los procedimientos de cierre financiero, y la auditoría independiente de la compañía no ha realizado ninguna revisión ni trabajo de aseguramiento sobre esta cifra. La cantidad final reportada en la próxima hoja de balance consolidada no auditada podría diferir de manera sustancial.
Viridian Therapeutics (VRDN)는 2025년 9월 30일 기준으로 현금, 현금성 자산 및 매매가능 증권의 예비 잔액이 약 $490.9 million이라고 발표했습니다. 이 수치는 감사 받지 않음이며 재무 마감 절차의 완료에 따라 달라질 수 있음를 전제로 하며, 회사의 독립 감사인은 이 수치에 대해 어떤 검토나 보증 작업도 수행하지 않았습니다. 다가오는 비감사 축약 재무상태표에 보고될 최종 금액은 실질적으로 다를 수 있습니다.
Viridian Therapeutics (VRDN) a annoncé un solde préliminaire d'environ $490.9 millions en espèces, équivalents de trésorerie et valeurs mobilières négociables au 30 septembre 2025. Le chiffre est non audité et sujet à l’achèvement des procédures de clôture financière, et l’auditeur indépendant de la société n’a effectué aucun examen ou travail d’assurance sur ce chiffre. Le montant final reporté dans le prochain bilan condensé non audité pourrait différer de manière significative.
Viridian Therapeutics (VRDN) gab einen vorläufigen Bestand an Bargeld, Zahlungsmitteln und handelbaren Wertpapieren in Höhe von ca. $490.9 million zum 30. September 2025 bekannt. Die Zahl ist nicht geprüft und unterliegt dem Abschlussverfahren, und der unabhängige Prüfer des Unternehmens hat keine Prüfung oder Bestätigungsarbeiten zu dieser Zahl durchgeführt. Der in der kommenden ungeprüften konsolidierten Bilanzposition gemeldete Endbetrag kann wesentlich abweichen.
Viridian Therapeutics (VRDN) أعلنت عن رصيد تمهيدي يقارب $490.9 million من النقد، وما يعادله من النقد، والأوراق المالية القابلة للتداول حتى 30 سبتمبر 2025. الرقم غير مدقق و يخضع لإتمام إجراءات الإغلاق المالي، ولم تقم المدقق المستقل للشركة بأي مراجعة أو عمل ضمان على هذا الرقم. قد يختلف المبلغ النهائي المبلغ عنه في بيان المركز المالي الموجز غير المدقق القادم بشكل جوهري.
Viridian Therapeutics (VRDN) 宣布，截至 2025年9月30日，现金、现金等价物和可交易证券的初步余额约为 $490.9 million。该数字为 未经审计，并且 尚未完成财务结账程序，公司的独立审计师未对该数字进行任何审核或保證工作。即将公布的未审计的简明合并资产负债表中的最终金额可能存在重大差异。
- None.
- None.
Insights
Preliminary liquidity disclosed: $490.9M as of Q3 end, unaudited.
Viridian Therapeutics provided an early liquidity snapshot of
The company states the figure is preliminary and unaudited, with closing procedures pending and no auditor assurance. The disclosure cautions the number may differ materially once the quarter is finalized.
Without additional operating metrics, this serves as a liquidity indicator only. Subsequent filings will clarify the final balance after closing procedures and any audit review applicable to interim reporting.
Viridian Therapeutics (VRDN) ha annunciato un saldo preliminare di circa $490.9 milioni in contanti, equivalenti in contanti e titoli negoziabili al 30 settembre 2025. La cifra è non revisionata e soggetta al completamento delle procedure di chiusura finanziaria, e l'auditor indipendente della società non ha eseguito alcuna revisione o attività di assicurazione su tale importo. L'importo finale riportato nel prossimo bilancio consolidato condensato non revisionato potrebbe differire in modo sostanziale.
Viridian Therapeutics (VRDN) anunció un saldo preliminar de aproximadamente $490.9 millones en efectivo, equivalentes de efectivo y valores negociables al 30 de septiembre de 2025. La cifra es no audita y sujeta a la finalización de los procedimientos de cierre financiero, y la auditoría independiente de la compañía no ha realizado ninguna revisión ni trabajo de aseguramiento sobre esta cifra. La cantidad final reportada en la próxima hoja de balance consolidada no auditada podría diferir de manera sustancial.
Viridian Therapeutics (VRDN)는 2025년 9월 30일 기준으로 현금, 현금성 자산 및 매매가능 증권의 예비 잔액이 약 $490.9 million이라고 발표했습니다. 이 수치는 감사 받지 않음이며 재무 마감 절차의 완료에 따라 달라질 수 있음를 전제로 하며, 회사의 독립 감사인은 이 수치에 대해 어떤 검토나 보증 작업도 수행하지 않았습니다. 다가오는 비감사 축약 재무상태표에 보고될 최종 금액은 실질적으로 다를 수 있습니다.
Viridian Therapeutics (VRDN) a annoncé un solde préliminaire d'environ $490.9 millions en espèces, équivalents de trésorerie et valeurs mobilières négociables au 30 septembre 2025. Le chiffre est non audité et sujet à l’achèvement des procédures de clôture financière, et l’auditeur indépendant de la société n’a effectué aucun examen ou travail d’assurance sur ce chiffre. Le montant final reporté dans le prochain bilan condensé non audité pourrait différer de manière significative.
Viridian Therapeutics (VRDN) gab einen vorläufigen Bestand an Bargeld, Zahlungsmitteln und handelbaren Wertpapieren in Höhe von ca. $490.9 million zum 30. September 2025 bekannt. Die Zahl ist nicht geprüft und unterliegt dem Abschlussverfahren, und der unabhängige Prüfer des Unternehmens hat keine Prüfung oder Bestätigungsarbeiten zu dieser Zahl durchgeführt. Der in der kommenden ungeprüften konsolidierten Bilanzposition gemeldete Endbetrag kann wesentlich abweichen.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| |
||
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code:
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
On October 21, 2025, the Company announced that while it has not finalized its full financial results for the quarter ended September 30, 2025, the Company expects to report that it had approximately $490.9 million of cash, cash equivalents and marketable securities as of September 30, 2025.
This amount is preliminary, has not been audited and is subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to this preliminary information and, accordingly, does not express an opinion or any other form of assurance with respect thereto. Consequently, this amount may differ materially from the amount that will be reflected in the Company’s unaudited condensed consolidated balance sheet as of September 30, 2025.
The information in this Item 2.02 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly provided by specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Viridian Therapeutics, Inc. | ||||||
| Date: October 21, 2025 | By: | /s/ Stephen Mahoney | ||||
| Stephen Mahoney | ||||||
| President and Chief Executive Officer | ||||||
FAQ
What did Viridian Therapeutics (VRDN) announce in its 8-K?
Is the $490.9 million cash figure for VRDN audited?
Could Viridian’s reported cash amount change?
What period does VRDN’s preliminary cash balance relate to?
Does the disclosure include earnings or revenue data for VRDN?
What is VRDN’s trading symbol and exchange?
